Biotherapeutic Pipeline

The Transendocardial Autologous Bone Marrow in Myocardial Infarction (TABMMI) study was a phase I open label trial treating patients with heart failure with autologous human bone marrow cells (hBMCs). One year followup results were presented in the American Heart Journal in 2007. Final two year results on twenty patients are pending publication. More information is available at:
http://clinicaltrials.gov/ct2/show/NCT00507468.

The Transendocardial Autologous Cells in Heart Failure Trial (TACHFT) is a Phase I/II randomized placebo controlled 68 patient trial comparing autologous human bone marrow cells (hBMCs) and autologous human mesenchymal cells (hMSCs) to placebo. Investigators are currently enrolling patients in the randomized study with the goal of completing enrollment in 2011. Enrollment in the study is open to patients suffering from Heart Failure. More information is available at:
http://clinicaltrials.gov/ct2/show/NCT00768066.

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) Study is a Phase I open label 30 patient trial comparing autologous human bone marrow cells (hBMCs), autologous human mesenchymal cells (hMSCs) to allogenic human mesenchymal cells (hMSCs). Investigators are currently enrolling patients in the randomized study also with the goal of completing enrollment in 2011. More information is available at:
http://clinicaltrials.gov/ct2/show/NCT01087996.

The “Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure” is an open label, 16 subject, Phase 1 dose-escalation study will demonstrate the initial safety of using ACRX-100 to treat heart failure in subjects with ischemic cardiomyopathy. More information is available at:
http://clinicaltrials.gov/ct2/show/NCT01082094.